Atossa Therapeutics (ATOS) Projected to Post Earnings on Monday

Atossa Therapeutics (NASDAQ:ATOS) is expected to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.

Atossa Therapeutics (NASDAQ:ATOS) last announced its quarterly earnings results on Tuesday, March 25th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, analysts expect Atossa Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Atossa Therapeutics Price Performance

Shares of NASDAQ:ATOS opened at $0.82 on Friday. The firm has a market capitalization of $106.49 million, a price-to-earnings ratio of -3.75 and a beta of 1.01. The business’s 50 day moving average price is $0.71 and its 200-day moving average price is $0.94. Atossa Therapeutics has a 1 year low of $0.55 and a 1 year high of $1.72.

Institutional Trading of Atossa Therapeutics

A hedge fund recently raised its stake in Atossa Therapeutics stock. Bank of America Corp DE raised its stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 51.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 111,475 shares of the company’s stock after purchasing an additional 37,809 shares during the period. Bank of America Corp DE owned about 0.09% of Atossa Therapeutics worth $105,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 12.74% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ATOS. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Atossa Therapeutics in a research report on Wednesday, March 26th. Ascendiant Capital Markets lifted their target price on Atossa Therapeutics from $7.00 to $7.25 and gave the company a “buy” rating in a research report on Monday, April 21st.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.